Status:
COMPLETED
Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine
Lead Sponsor:
GlaxoSmithKline
Conditions:
Diphtheria
Tetanus
Eligibility:
All Genders
10-18 years
Brief Summary
Pre-licensure studies of GSK Biologicals' Boostrix® have shown it to be generally safe and well-tolerated. This post-licensure study is designed to evaluate relatively uncommon/rare outcomes in a larg...
Detailed Description
Data collection through utilization of automated databases at the study site. The collaborator is Kaiser Permanente Vaccine Study Center.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Subjects between the age of 10 and 18 years (inclusive) who received a dose of Boostrix and who have safety follow-up information available
Exclusion
Key Trial Info
Start Date :
March 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2006
Estimated Enrollment :
10000 Patients enrolled
Trial Details
Trial ID
NCT00297856
Start Date
March 1 2006
End Date
December 1 2006
Last Update
January 13 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Oakland, California, United States, 94612